Breaking News

NEW YORK, Sept 18 – Bioinformatics company Informax of Rockville, Md., said Monday it had released version 3.0 of Genomax, a software package that includes modules for sequence analysis, gene expression analysis, and 3-dimensional protein structure. The

William Haseltine is a party pooper.

NEW YORK, Sept 18 – German food additives company SKW Nature Products has purchased Nanogen’s (Nasdaq: NGEN) molecular biology workstation, which will be used to test the effect of additives on humans, Nanogen said Monday. Terms of the deal were not disclosed.

A story from Wednesday, Sept 13 entitled "Applied Biosystems Sells 200 Sequencers to deCODE" has been corrected after a company spokesman revised the number of machines included in the deal.

MIAMI, Sept 14 - Compugen (Nasdaq: CGEN) of Tel Aviv, Israel announced Thursday the launch of Gencarta, a platform that provides access to the company's proprietary annotated genome, transcriptome and proteome databases. Users of Gencarta wi

NEW YORK, Sept 14 - Celera Genomics (NYSE: CRA) has licensed Proteome's BioKnowledge Library for distibution in the Celera Discovery System, Proteome said Thursday.

NEW YORK, Sept 14 - Third Wave Technologies said Thursday it had reached an agreement to provide Imperial College of Great Britain, Royal Brompton's Hospital, and the UK National Health Service Trust with access to its Invader operating system for S

MIAMI, Sept. 14 – The Institute for Computational Genomics (INCOGEN) of Clemson, SC, said Thursday it has set an Oct.

MIAMI, Sept 13 – Celera Genomics (NYSE:CRA) of Rockville, Md., said Wednesday that it had launched its Single-Nucleotide Polymorphism Reference Database for the human genome.

MIAMI, Sept. 13 – Incyte Genomics (Nasdaq: INCY) said Wednesday it planned to create a new revenue stream by offering exclusive licenses to pharmaceutical companies for its “deep SNP” genotyping data, which will link single-nucleotide differences to specific diseases.

MIAMI, Sept 13 – Sun Microsystems (Nasdaq: SUNW) of Palo Alto, Calif., said Wednesday that it is intensifying its push in life sciences by forming a new partnership effort and an informatics advisory council. The partnering plan, called the Discovery Informatics program, is an attempt

NEW YORK,   Sept 12 - Bruker Daltonics (Nasdaq: BDAL) of Billerica, Mass., said Tuesday it would sell 51 mass spectrometry machines to Geneva Proteomics as well as take an equity stake in the Swiss company. Fin

OXFORD, UK, Sept 12 - Oxford GlycoSciences (LSE: OGS) of Oxfordshire, UK, and Cambridge Antibody Technology (LSE: CAT) of Melbourn, UK, said Tuesday that they are cooperating to develop protein chip technology that will identify proteins by applying antibody-based mi

MIAMI, Sept 12 - Some 3,000 representatives of the genomics industry will arrive in Miami on Tuesday as the 12th International Genome Sequencing & Analysis Conference gets underway. The exhibition hall opens at 4 pm EDT and Craig Venter, the man who helped put genomics on the map,

MIAMI, Sept 12 – Lion Bioscience (Nasdaq: LEON, Neuer Markt: LIO) of Heidelberg , Germany said Tuesday it would incorporate Electric Genetics’ expressed sequence tags clustering tool into its SRS data integration platform, representing a vote of confidence for the So

PARIS, Sept 12 - In July, Geneva Proteomics of Switzerland made a bold announcement, saying it planned to become the international leader in industrialized proteomics. Armed with some of the leading brains in proteomics and $40 million in venture capita

This story has been updated from an early version with comments from IBM, Incyte NEW YORK, Sept 11 - Incyte Genomics (Nasdaq: INCY) of Palo Alto, Calif., said Monday it would incorporate IBM’s (NYSE: IBM) data management software i

NEW YORK, Sept. 11 -- Affymetrix (Nasdaq: AFFX) of Santa Clara, Calif., said Monday it had licensed technology for low and medium density DNA arrays to reagent-provider Takara Shuzo of Kyoto, Japan.

NEW YORK, Sept 11 - Genomics company Illumina (Nasdaq: ILMN) reported Monday pro forma net losses of $5.3 million, or 25 cents a share, for the company’s fiscal second quarter, compared with l

Here is some text for the article Here is bullet. More inforation for the comming wave of anacromonius junk The functionality is all there. We have a glitch with the homepage ordering and I am finishing the navigation now.

NEW YORK, Sept 8 – Salomon Smith Barney initiated coverage of Genaissance Pharmaceuticals (Nasdaq: GNSC) with a Venture, Buy rating and issued a 12-month price target of $32 a share. Genaissance of New Haven, Conn., was trading up 1 1/16, or 4.8 percent

NEW YORK, Sept 8 – Salomon Smith Barney initiated coverage of Genaissance Pharmaceuticals (Nasdaq: GNSC) with a Venture, Buy rating and issued a 12-month price target of $32 a share.  

Pages

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.